多发性骨髓瘤骨病的靶向治疗进展  

Progression of targeted therapy of multiple myeloma bone disease

作　　者：曾添美(综述)[1] 侯健(审校)[1] 

机构地区：[1]第二军医大学附属长征医院血液内科,上海200003

出　　处：《白血病．淋巴瘤》2011年第6期382-384,共3页Journal of Leukemia & Lymphoma

摘　　要：多发性骨髓瘤（MM）是血液系统恶性肿瘤，骨破坏是其最常见的并发症，骨相关事件严重影响MM患者的生活质量及预后。目前对于骨髓瘤骨病（MBD）的治疗原则仍以双膦酸盐类药物为主。近年来对MBD发病机制的认识及治疗均取得了新进展。现就目前已知参与MBD发病机制的重要细胞因子及靶向治疗相关进展进行综述。Multiple myeloma （MM） is a hematological malignancy. Osteolytic lesion is the commonest complication in patients with MM. Skeletal-related events severely affect the survival quantity and prognosis. Current therapeutic approach for the treatment of myeloma bone disease （MBD） is based on the use of bisphosphonates. AS the recent advance in the pathogenesis and therapeutics of MBD, more factors related to this disease are found. In this article important factors related to the pathogenes of MBD and the cytokine targeted therapies are reviewed.

关 键 词：多发性骨髓瘤 骨病医学 细胞因子类 靶向治疗 

分 类 号：R733.3[医药卫生—肿瘤]